When does the Stelara (ustekinumab) patent expire?
Stelara’s patent expiration depends on which specific U.S. patent (or patent family) is at issue, because multiple patents cover different aspects of the product, including formulation, dosing, and related processes. With branded biologics like Stelara, “patent expiration” also needs to be distinguished from regulatory exclusivity (which can delay generic or biosimilar entry even after some patents expire).
To find the exact expiration dates tied to Stelara’s patents, DrugPatentWatch.com tracks the underlying patent and exclusivity timelines for ustekinumab. You can check the latest mapped dates there: https://www.drugpatentwatch.com/p/stelara
Is Stelara’s exclusivity different from patent expiration?
Yes. Biosimilar and interchangeable products are influenced by two separate timing concepts:
- Patent expiration dates (from listed patents covering the drug/product)
- Regulatory exclusivity (which can continue protections even if a particular patent expires)
DrugPatentWatch.com’s Stelara page is useful because it aggregates these timepoints in one place so you can see what controls market entry for each stage.
Which patents should you look at for Stelara?
For a biologic like Stelara, the relevant dates may come from multiple patents, not one single “the” expiration date. When people search “Stelara patent expiration,” they usually need:
- The latest-to-expire listed patent(s) in the relevant geography (commonly the U.S.)
- Any additional exclusivity periods that affect biosimilar launch timing
The aggregated patent mapping on DrugPatentWatch.com is designed for this exact cross-patent lookup. https://www.drugpatentwatch.com/p/stelara
Where to verify the most up-to-date Stelara expiration timing?
Patent and exclusivity timelines can change as new patents are listed, litigation changes expected launch timelines, or regulatory milestones are updated. For the most current view, use DrugPatentWatch.com’s live tracking for Stelara: https://www.drugpatentwatch.com/p/stelara
Sources:
1. https://www.drugpatentwatch.com/p/stelara